Tresiba to launch in German market for Type 2 Diabetes subject to pricing agreement - Novo Nordisk
Novo Nordisk has decided to launch Tresiba (insulin degludec) in Germany after seeing signs of a more favourable pricing situation in that market. Tresiba was approved in the European Union last year, but despite Germany being Europe's biggest market Novo hesitated to market Tresiba because German authorities have been reluctant to support new and more expensive drugs.
In Germany pharmaceutical companies can initially set the price they want for new products and get a subsidy at the same time. Then, within a year, German authorities initiate an assessment process to find out if the price or subsidy should change. Within 12 months, Novo must agree on a price otherwise it will leave the market.
Tresiba is still not yet approved in the US.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.